Tucatinib
Overview
Tucatinib is a tyrosine kinase inhibitor used in combination with other drugs to treat HER2-positive breast cancer. It works by blocking the function of the HER2 receptor, effectively slowing the growth of cancer cells.
API suppliers (3)
Suppliers of Tucatinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 2 of 3 suppliers.
1 of 3 holds a GMP certificate on record in the EU or UK registers
- TAPI NL BVNetherlands1 active DMF
- SCINOPHARM TAIWAN LTDTaiwan1 active DMF
- DR REDDYS LABORATORIES LTD1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Tucatinib expires 27 Apr 2038 and exclusivity 19 Jan 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Tucatinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.